Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Shares Issued (2018 - 2023)

Spero Therapeutics (SPRO) has disclosed Shares Issued for 6 consecutive years, with $1000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Shares Issued changed 0.0% year-over-year to $1000.0, compared with a TTM value of $221000.0 through Dec 2024, changed 0.0%, and an annual FY2023 reading of $221000.0, down 47.38% over the prior year.
  • Shares Issued was $1000.0 for Q4 2023 at Spero Therapeutics, down from $220000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $40.0 million in Q2 2021 and bottomed at -$34.7 million in Q3 2021.
  • Average Shares Issued over 5 years is $3.7 million, with a median of $220000.0 recorded in 2023.
  • The sharpest move saw Shares Issued soared 11044.93% in 2019, then tumbled 1935.94% in 2021.
  • Year by year, Shares Issued stood at $15.4 million in 2019, then plummeted by 145.34% to -$7.0 million in 2020, then surged by 43.98% to -$3.9 million in 2021, then skyrocketed by 100.03% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023.
  • Business Quant data shows Shares Issued for SPRO at $1000.0 in Q4 2023, $220000.0 in Q3 2023, and $1000.0 in Q4 2022.